evipedia.ai
← Back

Tesamorelin for Health & Longevity

Evidence Review created on 10/28/2026 using AI4L / Opus 5.5

Also known as: Egrifta, Egrifta SV, Egrifta WR, TH9507, Tesamorelin Acetate

Motivation

Tesamorelin (Egrifta) is a lab-made copy of a brain hormone, given as a daily injection under the skin, that prompts the gland at the base of the brain to release more of the body’s own growth hormone in its natural pulses rather than supplying the hormone directly. That difference, together with its status as an approved prescription drug, sets it apart from the many growth-hormone-boosting injections now circulating in longevity circles.

Tesamorelin was developed for a narrow purpose: shrinking deep abdominal fat in people whose long-term antiviral treatment had redistributed their body fat. Because deep abdominal fat, fatty liver and fading memory are common concerns in aging, researchers have also studied it in people with obesity, fatty liver and early memory problems, and clinics now offer it well beyond its approved use.

This review examines the human evidence on tesamorelin’s benefits and risks, how it is used, monitored and sourced, and how that evidence applies to adults pursuing a longer healthy life.

Benefits - Risks - Protocol - Conclusion

The items below give high-level overviews of tesamorelin and of the growth hormone-releasing peptides it is grouped with in longevity practice.

Four items are listed because no further content discussed tesamorelin in substantial depth without falling under the exclusions. No qualifying content was found from Rhonda Patrick (a FoundMyFitness episode with Andrew Huberman names tesamorelin only in passing, and her other matches are members-only), Chris Kresser, Life Extension or Lifespan.io; their site searches returned no tesamorelin content.

Grokipedia

  • Tesamorelin

    An encyclopedia-style overview of tesamorelin’s chemistry, approval history, formulations and mechanism, useful for orientation, though AI-generated and not a primary source.

Examine

No Examine article on tesamorelin exists. Examine.com does not typically cover prescription medications, and tesamorelin is a prescription-only injectable drug.

ConsumerLab

No ConsumerLab article on tesamorelin exists. ConsumerLab does not typically cover prescription medications, and tesamorelin is a prescription-only drug that it has not tested.

Systematic Reviews

Three systematic reviews with meta-analyses pool the randomized placebo-controlled trials of tesamorelin, all conducted in people with HIV (human immunodeficiency virus) and treatment-related fat accumulation.

No systematic review is dedicated to tesamorelin’s principal long-term risks (new diabetes, cancer); the safety evidence in this section comes from the adverse-event pooling within the reviews above, whose pooled trials lasted no longer than 52 weeks. Most trials pooled in these reviews were sponsored by the manufacturer, Theratechnologies.

Mechanism of Action

Tesamorelin is human GHRH (growth hormone-releasing hormone, the brain signal that triggers growth hormone release), all 44 amino acids, plus a six-carbon fatty chain that slows breakdown (Egrifta WR FDA label, written by the manufacturer, Theratechnologies, and approved by the FDA).

  • Primary pathway: It binds GHRH receptors on pituitary somatotrophs (growth hormone-producing cells), enlarging the body’s own pulses of GH (growth hormone); the liver then makes IGF-1 (insulin-like growth factor 1, the main mediator of GH’s growth effects).
  • Fat and glucose effects: GH promotes lipolysis (breakdown of stored fat), especially visceral, and opposes insulin, explaining fat loss and higher blood sugar.
  • Proposed advantage over injected GH: Somatostatin (the brain’s GH brake) and IGF-1 feedback stay intact, keeping release pulsatile; still, 36% of users exceeded IGF-1 +3 SDS (standard deviation score, distance from the age-matched average) by 26 weeks.
  • Competing explanations: Metabolic gains may follow fat loss itself, since visceral-fat responders improved triglycerides and avoided the glucose rise seen in nonresponders (Stanley 2012, with manufacturer co-authors). Cognitive effects may involve IGF-1 or higher brain GABA (gamma-aminobutyric acid, the main calming neurotransmitter) (Friedman 2013).
  • Pharmacology: Bioavailability is under 4%, peak about 9 minutes, half-life 11 minutes, volume of distribution 4.8 L/kg (wide tissue spread); other pituitary hormones stay unchanged. No human metabolism study exists; as a peptide it is presumed cleaved by proteases, not CYP (cytochrome P450) liver enzymes, and it barely altered drugs cleared by CYP3A (the main drug-clearing CYP) (Teng 2013, manufacturer-run).

Historical Context & Evolution

  • Original use: GHRH was identified in the early 1980s, and a short GHRH fragment (sermorelin) was later used to diagnose and treat growth failure in children. Theratechnologies developed the stabilized full-length analogue TH9507 and tested it in conditions such as muscle wasting in chronic lung disease (NCT01388920, terminated after 3 participants).
  • Approval: After two manufacturer-sponsored phase 3 (large confirmatory) trials in people with HIV and abdominal fat gained on antiretroviral (anti-HIV) therapy (Falutz 2007), the FDA approved it in 2010 to reduce excess abdominal fat in HIV-associated lipodystrophy (abnormal fat redistribution) (Egrifta WR FDA label). Reformulations followed; Egrifta WR, reconstituted weekly, carries a label revised in March 2025 (Egrifta WR FDA label).
  • Path into health optimization: Interest traces to a 1990 trial in which GH given to 12 men over 60 raised lean mass 8.8% and cut fat 14.4% over six months (Rudman 1990). A later systematic review of 18 trial populations found smaller body-composition changes (fat −2.1 kg, lean mass +2.1 kg) and more edema (swelling from fluid), joint pain and carpal tunnel syndrome (wrist nerve compression causing hand numbness) (Liu 2007). Stimulating the body’s own pulses, rather than injecting GH, became the proposed alternative.
  • Evolving evidence: A 20-week trial in older adults reported better executive function (Baker 2012), and liver-fat trials followed. What has not changed is the absence of data on hard outcomes such as cardiovascular events, cancer or survival, so the question remains open in both directions.

Expected Benefits

High 🟩 🟩 🟩

Reduced visceral (deep abdominal) fat

Tesamorelin shrinks VAT (visceral adipose tissue, fat around the abdominal organs that is linked to cardiometabolic disease) while largely sparing fat under the skin; this is its approved indication. Placebo-controlled trials from Falutz (manufacturer-sponsored phase 3, Falutz 2010) and from Stanley (Stanley 2014) and Makimura (obese adults without HIV, Makimura 2012) at Massachusetts General Hospital agree. The loss reverses after stopping (Falutz 2008, a manufacturer-sponsored extension), and no trial has measured cardiovascular events.

Magnitude: A meta-analysis of five randomized controlled trials found 27.71 cm² less VAT than placebo (95% CI [confidence interval, the range likely to contain the true effect] −38.37 to −17.06) (Badran 2026); in the pooled phase 3 trials, VAT fell 24 cm² versus a 2 cm² rise on placebo at 26 weeks (Falutz 2010).

Medium 🟩 🟩

Reduced liver fat

Tesamorelin lowers liver fat in people with MASLD (metabolic dysfunction-associated steatotic liver disease, fat buildup in the liver not caused by alcohol). Two randomized trials from one research group, Stanley and colleagues at Massachusetts General Hospital, showed reductions in people with HIV (Stanley 2014, Stanley 2019); the 2019 trial also found less progression of fibrosis (liver scarring), a secondary endpoint. A completed trial in adults with obesity and fatty liver (NCT03375788) posted median liver-fat changes of −5.3% versus +3.6% on placebo, not compared between groups.

Magnitude: Liver fat fraction fell 4.1 percentage points more than placebo over 12 months (95% CI −7.6 to −0.7); 35% versus 4% reached a liver fat fraction below 5%, and fibrosis progressed in 10.5% versus 37.5% (Stanley 2019).

Lower cholesterol ⚠️ Conflicted

Tesamorelin modestly lowers cholesterol. A manufacturer-sponsored type 2 diabetes trial lowered total and non-HDL (non-high-density lipoprotein) cholesterol (Clemmons 2017), and a meta-analysis found lower total cholesterol but no significant pooled triglyceride change (Ditta 2026), although the phase 3 trial (Falutz 2007) and an obesity trial (Makimura 2012) lowered triglycerides. A 12-month randomized trial of 61 people found no effect on LDL (low-density lipoprotein) cholesterol, HDL cholesterol or triglycerides (Stanley 2019). Net reading: pooled data support a small total-cholesterol reduction, while single-trial triglyceride gains did not hold in pooled analysis.

Magnitude: Total cholesterol was 0.16 mmol/L lower than placebo in pooled trials (95% CI −0.27 to −0.06) (Ditta 2026); in one obesity trial, triglycerides fell 37 mg/dL more than placebo (95% CI −67 to −7) (Makimura 2012).

Better executive function in older adults ⚠️ Conflicted

In a 20-week placebo-controlled trial of 152 adults aged 55 to 87, healthy or with MCI (mild cognitive impairment, decline in memory or thinking short of dementia), tesamorelin 1 mg nightly improved executive function (planning, switching and self-control) (Baker 2012). This single-group finding is unreplicated: a 10-week blinded pilot in 22 older adults (Stewart 2026) and an open-label trial in 73 people with HIV (Ellis 2025) found no significant cognitive effect. Net reading: the larger blinded trial was positive, while the contrary trials were small, short or unblinded.

Magnitude: Executive function improved versus placebo with an effect size f of 0.37 (Cohen’s f, a standardized effect where 0.25 is medium and 0.40 large; P [probability of a result this large by chance] = .005); a weaker executive-function trend remained after a 10-week washout (P = .08) (Baker 2012).

Thinner carotid artery wall

In 60 abdominally obese adults without HIV and with low GH secretion, 12 months of tesamorelin reduced cIMT (carotid intima-media thickness, an ultrasound measure of artery-wall thickening) and CRP (C-reactive protein, a blood marker of inflammation) versus placebo (Makimura 2012). A meta-analysis of 119 trials found that slowing cIMT progression predicts fewer cardiovascular events, supporting its use as a surrogate (Willeit 2020). This is a single trial from one group.

Magnitude: cIMT changed by −0.03 mm versus +0.01 mm on placebo, a treatment effect of −0.04 mm (95% CI −0.07 to −0.01) (Makimura 2012).

Low 🟩

No benefit is graded Low: no benefit rests only on uncontrolled or indirect human data, and the remaining signals rest on unvalidated biomarkers (scan-measured lean mass, immune proteins, muscle energy recovery), which fall under Speculative.

Speculative 🟨

Increased lean body mass

Lean mass on DXA (dual-energy x-ray absorptiometry, a body-composition scan) rose 1.42 kg more than placebo in pooled trials (Badran 2026). This unvalidated biomarker partly reflects water; no trial has measured strength or function.

Lower immune activation

In a 12-month trial in people with HIV and fatty liver, 13 circulating immune-activation proteins fell on tesamorelin, matched by liver gene-expression changes (Stanley 2021). These are unvalidated biomarkers.

Improved muscle mitochondrial function

In obese adults with low GH, larger IGF-1 rises on tesamorelin correlated with faster muscle energy recovery after exercise (Makimura 2014). This is a within-group correlation on an unvalidated biomarker.

Benefit-Modifying Factors

  • Genetic polymorphisms: No genetic variant has been studied as a modifier of tesamorelin response; pharmacogenetic data are absent.
  • Baseline visceral fat and triglycerides: In phase 3 data, white race predicted larger visceral-fat loss; metabolic syndrome (clustered high waist, blood pressure, glucose, lipids) and triglycerides above 1.7 mmol/L were borderline (Mangili 2015, company-authored); 30% fell short of an 8% reduction (Lake 2021, company co-authored).
  • Baseline GH status: The non-HIV trial enrolled obese adults with reduced GH secretion (Makimura 2012); lean adults with normal GH secretion are untested, and smaller effects are plausible but unmeasured.
  • Baseline liver disease severity: In an exploratory analysis, higher baseline liver-disease activity scores tracked with larger score reductions on tesamorelin (Stanley 2019).
  • Sex: IGF-1 rise and body-composition changes were similar in men and women in older adults (Baker 2012); phase 3 trials were 86% men (Falutz 2007), limiting data in women.
  • Pre-existing conditions: Evidence comes mainly from HIV-associated lipodystrophy, fatty liver, obesity with low GH, and mild cognitive impairment; benefits in metabolically healthy adults are extrapolated.
  • Age: In adults aged 55 to 87, IGF-1 rose 117% and body fat fell, with similar effects in healthy adults and those with MCI (Baker 2012); the label notes no information above age 65 (Egrifta WR FDA label).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection-site reactions

Redness, itching, pain, irritation and bruising at abdominal injection sites are the most frequent adverse events. They were more common on tesamorelin in the manufacturer’s phase 3 program (Egrifta WR FDA label), in Stanley’s liver trial (Stanley 2019) and in Baker’s trial in older adults (Baker 2012). Reactions are usually mild, and rotating sites reduces them.

Magnitude: Injection-site reactions occurred in 25% of tesamorelin-treated versus 14% of placebo-treated patients over 26 weeks (Egrifta WR FDA label).

Fluid retention, joint and muscle pain, and nerve symptoms ⚠️ Conflicted

GH-induced fluid retention causes edema (swelling), arthralgia (joint pain), myalgia (muscle pain), paresthesia (tingling) and carpal tunnel syndrome (wrist nerve compression causing hand numbness). These appear in the manufacturer’s phase 3 data (Falutz 2010), in Baker’s independent trial (Baker 2012) and in a systematic review of GH-axis drugs (Sivakumar 2011). A meta-analysis of four trials found arthralgia similar to placebo and only nonsignificant excesses of myalgia and paresthesia (Ditta 2026). Net reading: fluid-related symptoms are consistently more frequent on tesamorelin, but the excess for each single symptom is small.

Magnitude: Over 26 weeks, arthralgia 13% versus 11% on placebo, myalgia 6% versus 2%, peripheral edema 6% versus 2%, paresthesia 5% versus 2%, and carpal tunnel syndrome 1% versus 0% (Egrifta WR FDA label).

Medium 🟥 🟥

Glucose intolerance and new-onset diabetes ⚠️ Conflicted

GH opposes insulin and can raise blood sugar. The label reports more new diabetes in phase 3; fasting glucose rose transiently at 2 weeks in one trial (Stanley 2014), and fasting insulin rose in adults with MCI (Baker 2012). A 12-month trial found no glucose difference (Stanley 2019); a diabetes trial kept control, but its full text (not abstract) reports HbA1c (glycated hemoglobin, average blood sugar over three months) +0.1% versus −0.5% on placebo (Clemmons 2017). Net reading: average glucose barely changes, but a minority develops hyperglycemia (high blood sugar).

Magnitude: HbA1c reached 6.5% or more in 5% of tesamorelin-treated versus 1% of placebo-treated patients, a hazard odds ratio (relative risk of the event over time) of 3.3 (95% CI 1.4 to 9.6) (Egrifta WR FDA label).

Hypersensitivity reactions and anti-drug antibodies

Allergic-type reactions (itching, redness, flushing, hives, rash) occurred in the manufacturer’s trials, and about half of users develop antibodies against tesamorelin, some cross-reacting with the body’s own GHRH; antibodies did not reduce efficacy (Egrifta WR FDA label). The evidence comes from one sponsor’s program. Pooled trials also showed a borderline excess of discontinuations for adverse events (Ditta 2026).

Magnitude: Hypersensitivity reactions affected 4% of tesamorelin-treated patients (the label gives no placebo rate for this category); rash occurred in 4% versus 2% on placebo; antibodies appeared in 50% at 26 weeks, no control group (Egrifta WR FDA label).

Low 🟥

Growth of existing or undetected cancers

Tesamorelin raises IGF-1, a growth factor; the label contraindicates it in active malignancy (Egrifta WR FDA label). Evidence is indirect, from the body’s own IGF-1 levels: a meta-analysis of case-control studies linked higher IGF-1 to prostate and premenopausal breast cancer (Renehan 2004). Trials were too short to detect cancer.

Magnitude: In a meta-analysis of case-control studies, comparing the 75th with the 25th percentile of IGF-1 gave an odds ratio (relative odds of disease) of 1.49 for prostate cancer (95% CI 1.14 to 1.95) and 1.65 for premenopausal breast cancer (95% CI 1.26 to 2.08) (Renehan 2004).

Higher mortality during acute critical illness

The label advises considering discontinuation in critically ill patients, extrapolating from injected GH (Egrifta WR FDA label). The evidence is indirect (high-dose GH, not tesamorelin): two randomized trials of GH in intensive-care patients found higher in-hospital mortality (Takala 1999).

Magnitude: Relative risk of death was 1.9 (95% CI 1.3 to 2.9) in the Finnish trial and 2.4 (95% CI 1.6 to 3.5) in the multinational trial with high-dose GH; mortality was 39% versus 20% and 44% versus 18% on placebo (Takala 1999).

Speculative 🟨

Worsening diabetic retinopathy

The label (Egrifta WR FDA label) advises monitoring people with diabetes for new or worsening retinopathy (retinal blood-vessel damage) because IGF-1 rises. The basis is mechanistic; a dedicated study (NCT01591902) was terminated without posted results.

Fetal harm in pregnancy

In rats, tesamorelin during organogenesis (organ formation) caused hydrocephaly (fluid buildup in the brain) in offspring at about two to four times the human exposure (Egrifta WR FDA label). No human data exist.

Faster biological aging from GH-axis stimulation

People with inherited GH-receptor deficiency have very little cancer or diabetes (Guevara-Aguirre 2011), and reduced GH signaling extends lifespan in mice. Whether raising GH shortens healthspan is untested; the concern is mechanistic.

Risk-Modifying Factors

  • Genetic polymorphisms: No genetic variant has been studied as a modifier of tesamorelin’s adverse effects.
  • Baseline glucose: Prediabetic glucose or HbA1c leaves less margin before the diabetes threshold; phase 3 trials excluded fasting glucose of 150 mg/dL or more and people with diabetes (Egrifta WR FDA label).
  • Baseline IGF-1: A high-normal starting IGF-1 leaves less room before +3 SDS (inferred, not studied); 36% exceeded that level by 26 weeks (Egrifta WR FDA label).
  • Sex: Women reported adverse events more often and accounted for 11 of 13 adverse-event dose reductions in older adults (Baker 2012).
  • Pre-existing conditions: Prior cancer, diabetic retinopathy, pituitary disease, heart failure or existing carpal tunnel syndrome raise the stakes of IGF-1 elevation or fluid retention; the label restricts use after malignancy to inactive, fully treated disease (Egrifta WR FDA label).
  • Age: In a systematic review of trials in healthy older adults, GH treatment increased edema, joint pain, carpal tunnel syndrome and glucose impairment (Liu 2007); the tesamorelin label has no data above age 65 (Egrifta WR FDA label).

Key Interactions & Contraindications

Documented interactions:

  • Simvastatin (a CYP3A substrate): No clinically relevant interaction; simvastatin exposure fell 8% and simvastatin acid 15%, within no-effect limits, so no dose change is needed (Teng 2013).
  • Ritonavir: No clinically relevant interaction; exposure fell about 9% and peak level 11%, so no dose change is needed (Teng 2013).
  • Drugs cleared by CYP450 liver enzymes: Corticosteroids (anti-inflammatory steroid drugs, e.g., prednisone), sex steroids (estradiol, testosterone), anticonvulsants (seizure-preventing drugs, e.g., carbamazepine) and cyclosporine; GH may alter their clearance and levels, so the label advises monitoring (Egrifta WR FDA label).
  • Glucocorticoid replacement (hydrocortisone, cortisone acetate, prednisone): GH inhibits conversion of cortisone to active cortisol, risking under-replacement in adrenal insufficiency (inadequate adrenal cortisol output); maintenance or stress doses may need to rise, especially with cortisone acetate and prednisone (Egrifta WR FDA label).
  • Glucose-lowering drugs (metformin, glipizide, insulin): No loss of diabetes control and similar medication adjustments versus placebo over 12 weeks in type 2 diabetes, though the full text (not abstract) reports HbA1c +0.1% on 2 mg versus −0.5% on placebo (Clemmons 2017); glucose monitoring therefore applies.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Injected GH (somatropin) and GH secretagogues (drugs that trigger GH release, e.g., ipamorelin, CJC-1295, ibutamoren): Additive GH stimulation would raise IGF-1 further and amplify fluid retention and glucose effects; IGF-1 monitoring is the mitigating step.
  • Oral estrogen (oral contraceptives, oral estradiol): First-pass liver exposure to estrogen blunts IGF-1 production, which may weaken the IGF-1 response; transdermal estrogen avoids this route.
  • Somatostatin analogues (octreotide, lanreotide): These suppress pituitary GH release and would oppose tesamorelin’s effect.
  • GLP-1 receptor agonists (injectable appetite- and glucose-lowering drugs that mimic glucagon-like peptide-1, e.g., semaglutide, tirzepatide): No shared metabolism; weight loss could offset tesamorelin’s glucose effect, and preserving lean mass during weight loss is a proposed rationale for pairing (Arora 2026, a narrative review).
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs, e.g., ibuprofen, naproxen): Their sodium and fluid retention could add to tesamorelin’s edema; limiting regular use during the first months reduces the overlap.
  • Over-the-counter high-dose niacin (1 g or more daily): Additive insulin resistance could raise glucose; fasting glucose and HbA1c checks cover this.
  • Supplements marketed to raise GH (arginine, ornithine, GABA, alpha-GPC [alpha-glycerylphosphorylcholine, a choline source]): Additive, though modest, GH stimulation; IGF-1 testing detects any excess.
  • Fish oil (omega-3 fatty acids): Additive triglyceride lowering; the combined effect is favorable but would confound attribution of lipid changes.
  • Testosterone therapy: Additive lean-mass gain and fluid retention, inferred from both raising lean mass and retaining sodium; edema and blood pressure checks cover the overlap.

Populations who should avoid Tesamorelin:

  • Disrupted hypothalamic-pituitary axis (the brain’s hormonal control chain over the pituitary gland): Hypophysectomy (surgical pituitary removal), hypopituitarism (pituitary underactivity), pituitary tumor or surgery, head irradiation or head trauma; contraindicated (Egrifta WR FDA label).
  • Active malignancy: Contraindicated; prior cancer must be inactive with treatment complete, and use stops at any recurrence (Egrifta WR FDA label).
  • Pregnancy: Contraindicated, because reducing visceral fat offers no benefit in pregnancy and animal data show fetal harm (Egrifta WR FDA label).
  • Known hypersensitivity to tesamorelin or its excipients (inactive ingredients: mannitol, hydroxypropyl betadex): Contraindicated (Egrifta WR FDA label).
  • Breastfeeding: The label advises against breastfeeding while on treatment (Egrifta WR FDA label).
  • Children and adolescents with open growth plates: Risk of accelerated linear growth; not indicated in pediatric patients (Egrifta WR FDA label).
  • Acute critical illness (after open-heart or abdominal surgery, multiple trauma, acute respiratory failure): The label advises considering discontinuation (Egrifta WR FDA label), based on higher mortality with high-dose GH (Takala 1999).
  • Persistent IGF-1 above +3 SDS: The label advises considering discontinuation, particularly when the efficacy response is not robust (Egrifta WR FDA label).
  • Active proliferative diabetic retinopathy: Inferred from the label’s retinopathy-monitoring precaution (Egrifta WR FDA label) and the growth-promoting effect of IGF-1 on retinal vessels; no human data with tesamorelin.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Early glucose checks: Fasting glucose and HbA1c at baseline, 2 to 4 weeks and 3 months limit new-diabetes risk; the label advises considering stopping if diabetes (HbA1c 6.5% or higher) develops without clear response (Egrifta WR FDA label).
  • IGF-1 ceiling: Measuring IGF-1 at 2 to 3 months limits excess growth-factor exposure; the label threshold for considering discontinuation is persistent IGF-1 above +3 SDS (Egrifta WR FDA label).
  • Dose reduction for fluid symptoms: Reducing the dose when edema, joint pain or hand tingling appear limits fluid-retention effects; trials adjusted doses for adverse events (Baker 2012) or reduced to 1 mg (Stanley 2019).
  • Injection-site rotation: Rotating injection sites across the abdomen and avoiding scars, bruises and the navel reduces injection-site reactions (Egrifta WR FDA label).
  • Cancer screening before starting: Up-to-date age-appropriate screening (mammography, colon screening, prostate-specific antigen) reduces the chance of stimulating an undetected cancer, as required in a recent trial protocol (NCT03375788).
  • Response check at 6 months: Repeating waist and visceral-fat measures at 26 weeks avoids continued exposure without benefit; the label advises considering discontinuation if glucose intolerance or persistent IGF-1 elevation lacks a clear efficacy response (Egrifta WR FDA label).
  • Approved product sourcing: Using the FDA-approved product at its labeled dose limits the IGF-1 excess, fluid retention and glucose rises listed under Risks, which unregulated “research” vials of uncertain dose and purity can amplify (Dominikowski 2026, a narrative review).
  • Eye examination in diabetes: A dilated retinal examination at baseline and periodically addresses the label’s concern about worsening diabetic retinopathy (Egrifta WR FDA label).
  • Pause during critical illness: Stopping during major surgery recovery, severe trauma or intensive care avoids the mortality signal seen with high-dose GH (Takala 1999).

Therapeutic Protocol

Timing, titration and cycling below reflect common practice unless cited; each dose is cited to its source.

  • Approved dose (Egrifta WR): 1.28 mg injected under the abdominal skin once daily; one vial is reconstituted weekly (Egrifta WR FDA label).
  • Other formulations: Egrifta SV is 1.4 mg daily (Egrifta SV FDA label); the original formulation used in most trials was 2 mg daily (Falutz 2010). The labels state formulations are not substitutable.
  • Lower-dose regimen in older adults: 1 mg nightly, 30 minutes before bedtime, for 20 weeks, used in the cognition trial (Baker 2012).
  • Practitioner approach: Peptide clinicians such as Craig Koniver describe combining tesamorelin with other GH-releasing peptides under physician oversight (Huberman Lab episode); no published dose for such stacks has been tested in trials.
  • Competing approaches: The label-based approach uses tesamorelin alone at the approved dose with glucose and IGF-1 monitoring; integrative clinics use lower or stacked regimens; alternative routes to visceral-fat loss include exercise, caloric restriction and GLP-1 receptor agonists.
  • Who popularized it: The Massachusetts General Hospital metabolism group (Grinspoon, Stanley, Fourman) led much of the trial work, and peptide-focused clinics popularized off-label use.
  • Time of day: The label sets no time (Egrifta WR FDA label); bedtime dosing aligns with the natural nighttime GH pulse and was used by Baker (Baker 2012); morning dosing is also common.
  • Half-life: Plasma half-life is about 11 minutes (Egrifta WR FDA label), yet IGF-1 stays raised over the day, supporting once-daily dosing.
  • Single versus split dose: All trials used a single daily injection; splitting has not been studied.
  • Genetic polymorphisms: No variant guides dose selection; genotyping has no role.
  • Sex: Women had more adverse events and dose reductions at 1 mg (Baker 2012); starting low and titrating by IGF-1 is common in women.
  • Age: Older adults tolerated 1 mg nightly (Baker 2012); the label has no data above 65, so lower starting doses are common.
  • Baseline biomarkers: High-normal IGF-1 or prediabetic glucose favor lower starting doses; high triglycerides and metabolic syndrome showed borderline trends toward better visceral-fat response (Mangili 2015).
  • Pre-existing conditions: Fatty liver trials used 2 mg daily for 12 months (Stanley 2019); in type 2 diabetes, 1 mg and 2 mg daily for 12 weeks kept control, though HbA1c rose slightly at 2 mg (Clemmons 2017).

Discontinuation & Cycling

  • Ongoing rather than short-term: Benefits last only while treatment continues; visceral fat reaccumulated after switching to placebo (Falutz 2008), so use is open-ended for anyone aiming to keep the effect.
  • Withdrawal effects: No withdrawal syndrome is reported; IGF-1 returned to baseline within 10 weeks of stopping (Baker 2012).
  • Tapering: Trials switched participants directly to placebo without reported withdrawal problems, so no tapering protocol is described.
  • Cycling: No trial has tested cycling; on-off schedules used in clinics have no efficacy data, and fat regain after stopping argues against long breaks.
  • Antibodies after stopping: 18% of antibody-positive patients were still positive 6 months after stopping (Egrifta WR FDA label), relevant to anyone restarting.

Sourcing and Quality

  • Branded product: Egrifta WR and Egrifta SV, made by Theratechnologies, are FDA-approved tesamorelin products; they require a prescription (Egrifta WR FDA label) and are usually dispensed through specialty pharmacies.
  • Formulation differences: Egrifta WR (11.6 mg vial, weekly reconstitution with bacteriostatic water) and Egrifta SV (2 mg vial, daily reconstitution) differ in dose and handling and are not substitutable (Egrifta WR FDA label).
  • Unregulated “research” vials: Tesamorelin sold online as a research chemical has uncertain identity, purity and dose, and stacking with other peptides compounds the uncertainty (Dominikowski 2026, a narrative review).
  • What to look for outside the branded product: A licensed US pharmacy, a batch certificate of analysis confirming identity by mass spectrometry, and sterility and endotoxin (bacterial toxin) testing.
  • Storage: Reconstituted Egrifta WR is kept at room temperature and discarded 7 days after mixing (Egrifta WR FDA label).

Practical Considerations

  • Time to effect: IGF-1 rises within weeks; visceral-fat reduction was assessed at 26 weeks, liver-fat change at 6 to 12 months, and cognitive change at 10 to 20 weeks (Falutz 2010, Stanley 2019, Baker 2012).
  • Common pitfalls: Expecting scale weight loss (the label calls the drug weight-neutral; Egrifta WR FDA label), skipping glucose checks, buying unverified vials, stacking several GH-raising peptides without IGF-1 testing, and stopping without a plan for fat regain.
  • Nonresponse: About 30% of treated participants did not reach an 8% visceral-fat reduction (Lake 2021); a measured response at 6 months separates responders from nonresponders.
  • Regulatory status: FDA-approved only for excess abdominal fat in HIV-associated lipodystrophy; other uses are off-label (Egrifta WR FDA label). GHRH analogues, tesamorelin included, are prohibited in sport by WADA (World Anti-Doping Agency) (WADA Prohibited List).
  • Cost and access: The branded drug costs thousands of US dollars per month, and insurers generally cover it only for the approved indication.
  • Payer incentives: Cheaper routes to visceral-fat loss (exercise, diet, generic drugs) give insurers and health systems a financial incentive to restrict tesamorelin coverage, a potential structural bias in coverage rules and in which trials get funded.
  • Manufacturer-dominated evidence: Most trials were sponsored by Theratechnologies or run by investigators who co-led its phase 3 program, so independent replication remains limited.

Interaction with Foundational Habits

  • Sleep: No direct effect shown; tesamorelin at bedtime did not change sleep quality in older adults (Baker 2012). Infused native GHRH impaired deep sleep in young women (Mathias 2007), so sleep tracking in women is a practical consideration.
  • Nutrition: Indirect and potentiating; the drug is weight-neutral, so visceral-fat loss adds to rather than replaces calorie control. High blood glucose suppresses GH release, so injecting two or more hours after the last meal is common practice; limiting alcohol supports liver-fat goals.
  • Exercise: Potentiating in theory; exercise itself stimulates GH, and the lean-mass gain lacks functional data. The ongoing TRIUMPH trial tests tesamorelin with home-based exercise for physical function (NCT06554717); resistance training remains the route to functional strength.
  • Stress management: Indirect; GH reduces conversion of cortisone to active cortisol in fat and liver (Egrifta WR FDA label), which may lessen cortisol-driven visceral fat; no study has measured stress outcomes, and chronic stress, which promotes visceral fat, works against the drug.

Monitoring Protocol & Defining Success

Baseline testing: Before the first injection, fasting glucose, HbA1c, IGF-1 and a fasting lipid panel are drawn, and waist circumference is recorded. Visceral fat is measured by DXA or MRI (magnetic resonance imaging), liver fat by MRI fat fraction in anyone with suspected fatty liver, and age-appropriate cancer screening and, in people with diabetes, a retinal examination are completed. These values define each person’s starting point and identify reasons not to start.

Ongoing monitoring: Fasting glucose is rechecked at 2 to 4 weeks, when early rises appear (Stanley 2014). IGF-1, HbA1c and lipids follow at 3 months. At 6 months, waist and visceral fat are remeasured to judge response, and liver fat at 6 to 12 months. Thereafter, glucose, HbA1c and IGF-1 are repeated every 6 months, with symptom review at each visit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
IGF-1 Within the age-specific range; consider stopping if persistently above +3 SDS (Egrifta WR FDA label) Safety check and expected change: confirms response, flags excess Conventional reference range: the laboratory’s age- and sex-specific range (about −2 to +2 SDS). Source: Egrifta WR FDA label. Use the same laboratory over time, as assays differ.
HbA1c Below 5.7% (American Diabetes Association) Safety check: rise toward 6.5% changes use Conventional reference range: 4.0–5.6%. Source: ADA 2026 Standards (ADA, American Diabetes Association); the ADA receives pharmaceutical-industry sponsorship, but its diagnostic thresholds generate no member revenue. No fasting needed.
Fasting glucose Below 100 mg/dL (American Diabetes Association) Safety check: early rises signal intolerance Conventional reference range: 70–99 mg/dL. Source: ADA 2026 Standards; the ADA receives pharmaceutical-industry sponsorship, but its diagnostic thresholds generate no member revenue. Draw after an 8-hour fast; pair with HbA1c.
Triglycerides Below 150 mg/dL (NCEP ATP III) Expected change: falls in responders Conventional reference range: below 150 mg/dL. Source: NCEP ATP III (NCEP, the National Cholesterol Education Program; ATP III, its third Adult Treatment Panel; a government program without member revenue). Fasting sample preferred.
Visceral fat (DXA or MRI) Below 140 cm² (Mangili 2015, a level associated with lower risk) Expected change: primary response marker No conventional laboratory reference range exists. Source: Mangili 2015. Use the same scanner and software for repeat scans.
Waist circumference Below 102 cm in men and 88 cm in women (NCEP ATP III) Expected change: low-cost response proxy No conventional laboratory reference range exists. Source: NCEP ATP III. Measure at the top of the hip bone after exhaling.
Liver fat fraction (MRI or spectroscopy) Below 5% (threshold used in Stanley 2019) Expected change in people with fatty liver No conventional laboratory reference range exists; 5% fat fraction is the diagnostic cutoff for steatosis (fatty liver). Source: Stanley 2019. Use the same imaging method each time.

Qualitative markers:

  • Joint pain, swelling of hands or ankles, and hand numbness or tingling (fluid-retention signals)
  • Injection-site redness, itching or bruising
  • Belt size and abdominal appearance
  • Energy, sleep quality and subjective mental sharpness
  • Thirst or frequent urination (possible rising glucose)

Emerging Research

  • TRIUMPH physical function trial: Phase 2 (mid-stage), 100 sedentary adults aged 50 to 80 with HIV at frailty risk; tesamorelin or placebo plus home exercise, 24 weeks; primary endpoint chair-stand time; recruiting, ends 2028 (NCT06554717). A positive result would show functional benefit from lean-mass gains; a null result would suggest they are mostly fluid.
  • Peripheral nerve injury trial: Phase 2, 36 participants, tesamorelin 2 mg to enhance nerve regrowth and limit muscle wasting; primary endpoint pinch strength; recruiting, completion December 2027 (NCT03150511). A positive result would add a regenerative use; a null result would leave the case resting on metabolic effects.
  • Fatty liver in obesity trial: Completed January 2025 with results posted (51 enrolled): median liver fat −5.3% versus +3.6% on placebo, liver-inflammation and fibrosis scores unchanged in both arms, not compared between groups; no journal publication was found (NCT03375788).
  • GHRH and mild cognitive impairment trial: Phase 1 (early-stage), 22 participants, tesamorelin 1 mg daily for 10 weeks; completed January 2019, no results posted on the registry (NCT02553603). Published results showed no significant change in cognition or other study measures (Stewart 2026).
  • Lean-mass preservation with GLP-1 drugs: Tesamorelin is among agents proposed to limit muscle loss during GLP-1-driven weight loss (Arora 2026, a narrative review); no registered trial tests the combination, which could strengthen or weaken the body-composition case.
  • Long-term safety: Pooled trials span at most 52 weeks and flag limited long-term safety data (Ditta 2026); cancer, diabetes and cardiovascular outcomes over years could weaken or strengthen the case.
  • Replication in healthy older adults: The cognitive signal rests on one trial (Baker 2012), against a small null blinded pilot (Stewart 2026) and a null open-label trial in HIV (Ellis 2025); an adequately sized blinded replication would settle whether the benefit is real.

Conclusion

Tesamorelin is an approved prescription drug that prompts the body to release more of its own growth hormone. Its best-supported effect is a reduction of deep abdominal fat, shown consistently across several research groups, and it does not lower body weight. Smaller benefits on liver fat, blood fats, artery-wall thickness and, in older adults, thinking skills have moderate support, mostly from people on long-term antiviral treatment or with obesity or fatty liver rather than from healthy adults; gains in lean tissue rest on scans that may partly count retained water.

The downsides are concrete. Skin reactions where it is injected, swelling and joint pain are common, blood sugar rises in some users, and the drug raises a growth signal linked to cancer in population studies. The benefits fade within months of stopping, so lasting effects require ongoing daily injections, regular blood tests and a high price.

The evidence base is short-term, mostly limited to six to twelve months, and largely produced by the manufacturer or by investigators closely tied to its development, a conflict of interest that weighs on how firmly the findings can be read. No study has measured heart attacks, cancer or survival. For health-focused adults with excess deep abdominal fat or fatty liver who accept monitoring, tesamorelin offers a measurable change in body fat distribution; for healthy adults pursuing longer life, its value remains uncertain, and the products sold outside pharmacies add a further layer of uncertainty about what is actually being injected.

Top - Benefits - Risks - Protocol